logo
Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Not Private Clinics: New Poll

Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Not Private Clinics: New Poll

Business Wire4 hours ago

TORONTO--(BUSINESS WIRE)--Nearly three in four Ontarians believe the government should prioritize spending on public hospitals rather than private clinics, in a poll conducted following the recent budget announcement of $280 million being shunted to private, for-profit clinics. Eighty-four per cent of Ontarians also said they believe public hospitals are understaffed.
The Nanos poll was conducted between May 27 and June 1, surveying 1,017 Ontarians over the age of 18. The poll was commissioned by CUPE's Ontario Council of Hospital Unions (OCHU-CUPE), which released a supplementary report on the ongoing privatization of hospital services.
'This poll shows there is overwhelming opposition to this government's plans to privatize hospital surgeries,' said Michael Hurley, president of OCHU-CUPE, which represents 50,000 hospital and long-term care staff. 'The public understands that spending on private, for-profit clinics and agencies is much more expensive, comes with poorer outcomes and duplicates infrastructure and administration. The vast majority wants our resources allocated to public health care.'
While the government expands funding to for-profit clinics, over four in five Ontarians (84%) believe there is not enough staff in public hospitals – including 82 per cent of Ontario PC supporters.
In the recent budget health care funding increased two per cent, well below the annual health care inflation of 5.2 per cent, noted the union.
After significant privatization of cataract surgeries, the government plans to expand private, for-profit delivery of other procedures including knee and hip replacements as well as diagnostics. In 2023, Premier Doug Ford suggested that up to 50 per cent of surgeries could be performed outside of hospitals.
'This is startling given that for-profit surgeries in Ontario are twice as expensive as those performed in public hospitals,' said Hurley.
The OCHU-CUPE report highlights the findings of a 2024 Canadian Medical Association Journal study showing that privatization of cataract operations resulted in surgical rates increasing by 22 per cent for the wealthiest Ontarians while declining for everyone else. Access to surgeries for the poorest people in Ontario declined nine per cent. The study noted that hospitals provided equal access to care.
At the media conference, the union showed a visual representation of this inequality through a map of Ontario's neighbourhoods, colour-coded by socioeconomic status. The yellow areas representing the wealthiest neighbourhoods showed the most affluent Ontarians are clustered in enclaves that are barely visible amidst a sea of blue (representing the bottom 80 per cent of residents).
'People can't afford to pay thousands of dollars for health care,' Hurley said. 'The great majority of Ontarians reject this expensive privatization that bakes in inequalities and greatly reduces access.'
The Ontario Health Coalition has documented hundreds of cases of private, for-profit clinics billing patients for medically necessary services – which is illegal – and add-on services that patients felt compelled to purchase.
Sixty-seven per cent of respondents to the Nanos poll said it was unacceptable for private clinics to charge people for medically necessary services.
The union expressed concerns about the acceleration of privatization, citing the CMAJ study's findings showing that since expansion of public funding for cataract surgeries in Ontario, 22.5 per cent of these procedures were performed in private clinics.
:gv/cope491

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance
Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Yahoo

time2 hours ago

  • Yahoo

Phillips Medisize Launches TheraVolt Medical Connectors to Support Next-Gen Device Integration, Connectivity and Performance

Designed to address increasing demand for advanced medical connectors in growing specialties such as electrophysiology Enhanced cross-platform compatibility helps simplify device integration, increase longevity of capital equipment, reduce customization development time and lower costs The first of several Phillips Medisize–branded medical connectors planned to launch over the next 18–24 months, TheraVolt™ provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with Phillips Medisize's 60+ years of medical experience HUDSON, Wis., June 09, 2025--(BUSINESS WIRE)--Phillips Medisize, a Molex company and a leader in the design, engineering and manufacturing of medtech, pharmaceutical drug delivery and in vitro diagnostic devices, announces the launch of TheraVolt™ Medical Connectors. As the first medical connectors launched under the Phillips Medisize brand, TheraVolt is engineered to optimize device integration, functionality, reliability and performance. TheraVolt provides device engineers enhanced functionality, offering solutions to handle both signals and high voltage lines. Emerging trends in electrophysiology (EP), most notably the rapid adoption of pulsed field ablation (PFA) technology, are driving increased demand for advanced medical connectors that support higher pin count densities and compact design. With enhanced cross-platform compatibility, TheraVolt Medical Connectors help simplify medical device integration, increase longevity of capital equipment, reduce customization development time and lower costs. This can enable more efficient solutions and greater flexibility for medical device companies developing PFA treatment for patients living with atrial fibrillation. "With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers," said Pete Soupir, vice president, MedTech segment at Phillips Medisize. "TheraVolt Medical Connectors empower our medical device customers to develop next-gen EP devices with enhanced integration, connectivity and performance. Their high pin count and high voltage clearance is particularly valuable in medical devices used in electrophysiology treatments, with multiple therapy options, complex functions and expanded data collection." These tailored offerings for medical applications leverage 80+ years of global leadership in interconnect solutions from Molex, combined with more than 60 years of medical experience from Phillips Medisize. TheraVolt Medical Connectors support next-generation medical device integration and performance through: High Pin Count and Voltage Clearance: Enables the integration of more functionalities, allowing medical device engineers to design multi-therapy medical devices with expanded capabilities, advanced functions and increased data collection. Design Flexibility and Customization: Available off-the-shelf with the flexibility to be tailored to meet diverse application demands, with customizable configurations for specific pin counts and precise electrical requirements. Sterilization Compatibility: Engineered to withstand multiple autoclave cycles, maintaining integrity and performance even under repeated exposure to harsh sterilization processes. Safety and Reliability: Designed to support compliance with IEC and IPC requirements, helping to promote dependable operation in medical applications. Additional Phillips Medisize Medical Connectors are in development and will be delivered over the next 18–24 months. Learn more about TheraVolt Medical Connectors at and About Phillips Medisize Phillips Medisize, a Molex company, collaborates with leading medical technology, pharmaceutical and in vitro diagnostic companies to design, engineer and manufacture lifesaving innovations. A contract development and manufacturing organization (CDMO), Phillips Medisize leverages its 60 years of expertise and globally renowned capabilities to collaborate with customers to deliver products and solutions that annually help millions of patients, healthcare professionals and individuals live healthier, more productive lives. For more information, visit About Molex Molex is a global electronics leader committed to making the world a better, more-connected place. With a presence in more than 38 countries, Molex enables transformative technology innovation in the consumer device, aerospace and defense, data center, cloud, telecommunications, transportation, industrial automation, and healthcare industries. Through trusted customer and industry relationships, unrivaled engineering expertise, and product quality and reliability, Molex realizes the infinite potential of Creating Connections for Life. For more information, visit View source version on Contacts Media Contact: Merryman CommunicationsHelen Winklerhelen@

We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication
We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication

Yahoo

time3 hours ago

  • Yahoo

We Need to Talk About Erectile Dysfunction: 38% of Canadian Men Don't Know You Need a Prescription for ED Medication

– This Men's Health Week, Phoenix is addressing misconceptions around erectile dysfunction to raise awareness for treatment and break the social stigma – TORONTO, June 09, 2025--(BUSINESS WIRE)--For Men's Health Week (June 9 to 15), Phoenix, Canada's leading digital health clinic for men, is raising awareness to break the stigma around erectile dysfunction (ED), a medical condition that affects almost half (49.4%) of Canadian men aged 40 to 88. ED is a medical condition that prevents the ability to get and maintain an erection sufficient for sexual intercourse, with a range of potential causes that could each contribute to the condition, including age, medications, injury, and lifestyle. Despite its prevalence, Phoenix's survey of more than 1,500 Canadians found that there is a significant lack of awareness around ED and its treatment, likely contributing to stigma surrounding the condition. CANADIANS UNDERESTIMATE THE REACH OF ED Despite nearly half of Canadian men over 40 being affected, ED's prevalence is underestimated, driving undue stigma. In fact, almost half of Canadians (45%) think that ED affects less than 40 per cent of men 40+. Twenty-seven per cent of Canadians think it affects less than 30 per cent of men 40+. While Canadians underestimate the prevalence of ED in middle-aged and older men, many are also unaware that the condition can also impact younger men. The survey found that 64 per cent of Canadians don't know that men aged 35 and younger can experience ED. That percentage grows as you look at younger men, with 71% of Canadians unaware that men aged 18 to 25 can be affected. This common misconception can contribute to the stigma around experiencing ED as a younger man, making it more difficult for those struggling to seek care. "ED is a medical condition that men of all ages can experience. There shouldn't be anything awkward about it, but there is. We're trying to change that," says Kevin Bache, co-founder and co-CEO of Phoenix. "While it may feel uncomfortable, men need to understand what the condition entails, and not shy away from being proactive in discussing it with a doctor. The sooner you get started, the better your chances are at finding mental and physical relief." WIDESPREAD MISUNDERSTANDING OF ED MEDICATION Treatment for ED and its underlying cause can vary greatly depending on a patient's prognosis, however, medication is a common and effective treatment. Despite this fact, Phoenix's survey found 18 per cent of men are unsure if ED is treatable with medication, revealing a lack of awareness that may leave many suffering needlessly. The data also highlighted a concerning gap in awareness that ED medication requires a prescription. Thirty-eight per cent of men are unsure or don't think they need a prescription to purchase medication, such as Viagra, for ED. However, the lack of awareness is most significant among younger Canadians. About three in five Gen Z (59%) don't know that you need a prescription for ED medication: 32 per cent are unsure, and 27 per cent don't think you need a prescription at all. It is important that Canadians know that ED medication requires a prescription from a medical professional, as they may otherwise be vulnerable to purchasing unauthorized sexual enhancement products sold over the counter, which Health Canada warns could pose serious health risks. "It's no surprise that people aren't aware of the prevalence of ED – it just doesn't get talked about enough. But the good news is, there are treatment options, and with more openness and awareness, more people can seek support immediately," says Gavin Thompson, co-founder and co-CEO of Phoenix. "We built Phoenix to change that. Our mission is simple: make expert care easy to access – fast, discreet, and doctor-led. We're building a future where men take charge of their health with confidence." WHAT CANADIANS NEED TO KNOW ABOUT ED ED can affect men at any age, but it becomes more common as you get older. ED is more common than you may think, affecting almost half of Canadian men aged 40 to 88. Many factors can cause ED, including: low levels of testosterone, nervous dysfunction, blood flow complications, medications, medical conditions, lifestyle factors, obesity, diet, drug abuse, smoking, and emotional or psychological complications. ED is highly treatable, but the first step is consulting a medical professional. Treatment for erectile dysfunction and its underlying cause can vary greatly, making it important to consult a medical professional to receive a diagnosis and devise an effective treatment strategy. ED medication requires a prescription from a medical professional. Phoenix is currently available in Ontario, Alberta, British Columbia, Saskatchewan, Manitoba, Nova Scotia, New Brunswick, PEI, and Newfoundland. To learn more about Phoenix's ED support, visit ABOUT PHOENIX Phoenix is Canada's leading digital health clinic for men, specializing in three areas of treatment – erectile dysfunction, weight loss, and hair loss. The telehealth platform facilitates access to licensed Canadian physicians, treatment options, and free, discreet shipping of prescription medication from coast to coast. Visit to learn more. SURVEY METHODOLOGY These findings are from a survey conducted by Phoenix from May 20th to May 22nd, 2025, among a representative sample of 1509 online Canadians who are members of the Angus Reid Forum. The survey was conducted in English and French. For comparison purposes only, a probability sample of this size would carry a margin of error of +/-2.53 percentage points, 19 times out of 20. View source version on Contacts MEDIA Anne-Marie TrembleSenior Account Manager, Talk Shop Mediaannemarie@ 613-914-3551

Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through Specialized Language Solutions
Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through Specialized Language Solutions

Business Wire

time3 hours ago

  • Business Wire

Sesen Launches with a Singular Mission: Advancing Life Sciences Globally Through Specialized Language Solutions

BOSTON--(BUSINESS WIRE)--Today marks the official launch of Sesen, a next-generation language services company purpose-built to meet the complex demands of the life sciences industry. Specializing exclusively in translation, localization, and AI-enhanced linguistic solutions for pharmaceutical, biotechnology, medical device, CRO, and regulatory organizations, Sesen combines industry expertise with cutting-edge technology to deliver fast, accurate, and fully compliant multilingual communications across 150+ languages. Built by industry veterans, Sesen is redefining how life sciences companies manage language workflows, from clinical trial documentation and regulatory labeling to patient communications and digital health platforms. At the core of its offering is SesenGPT, a proprietary AI engine trained on life sciences terminology and optimized for medical and regulatory content. Key Capabilities Include: Regulatory-compliant translations aligned with EMA, FDA, and PMDA guidelines ISO 17100, ISO 9001:2015, and ISO 13485:2016 certified quality management AI-enabled hybrid workflows for clinical trial translations, pharmacovigilance, and labeling Native linguists and MD/PhD medical reviewers for domain-specific accuracy Scalable language solutions integrated with sponsor CMS and eTMF systems 'Life sciences innovation is increasingly global, but language remains a critical barrier,' said Dr. Vladimir Misik, VP of Global Clinical Trial Strategy. 'We launched Sesen to solve this challenge with unmatched specialization, seamless technology integration, and the linguistic precision this industry demands.' Diego Di Leva, Sesen's VP of Global Operations, and a certified ISO 9001 and ISO 13485 auditor, added: "At Sesen, language quality is not an afterthought, it's built into the DNA of every project. Our quality assurance framework is grounded in international standards and supported by linguists with deep domain expertise, ensuring every deliverable meets the highest regulatory and scientific expectations." With a growing network of linguists, in-country reviewers, and regulatory consultants, Sesen supports top pharmaceutical and biotechnology companies with on-time, compliant delivery of multilingual assets for product launches, clinical trials, and regulatory submissions. About Sesen Sesen is a specialized language solutions provider exclusively serving the life sciences industry. Focused on clinical, regulatory, and commercial translation, Sesen supports pharmaceutical, biotech, medical device, and CRO clients in 150+ languages. The company combines native linguists, medical professionals, and ISO-certified workflows with proprietary AI technology to deliver faster, more accurate, and compliant content. From clinical trial support to product localization, Sesen enables life sciences organizations to operate with linguistic confidence and regulatory precision.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store